Merus (NASDAQ:MRUS) Receives $72.70 Average PT from Brokerages

Shares of Merus (NASDAQ:MRUSGet Free Report) have received an average rating of “Buy” from the twelve analysts that are covering the stock, MarketBeat Ratings reports. Twelve investment analysts have rated the stock with a buy recommendation. The average 1-year target price among brokers that have covered the stock in the last year is $73.60.

Several research firms have weighed in on MRUS. William Blair reissued an “outperform” rating on shares of Merus in a research note on Monday, April 22nd. Guggenheim increased their target price on Merus from $57.00 to $93.00 and gave the company a “buy” rating in a report on Tuesday, May 28th. Truist Financial lifted their price target on Merus from $69.00 to $88.00 and gave the stock a “buy” rating in a research note on Tuesday, June 4th. Stifel Nicolaus increased their price objective on Merus from $90.00 to $99.00 and gave the company a “buy” rating in a research note on Monday. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $66.00 target price on shares of Merus in a research note on Friday, May 24th.

Read Our Latest Analysis on Merus

Merus Stock Performance

Shares of NASDAQ:MRUS opened at $55.77 on Tuesday. The firm has a market capitalization of $3.27 billion, a PE ratio of -20.13 and a beta of 1.10. Merus has a 52-week low of $19.81 and a 52-week high of $61.61. The firm has a fifty day moving average of $47.79 and a 200 day moving average of $40.99.

Merus (NASDAQ:MRUSGet Free Report) last posted its quarterly earnings data on Wednesday, May 8th. The biotechnology company reported ($0.59) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.83) by $0.24. The firm had revenue of $7.89 million during the quarter, compared to analysts’ expectations of $8.94 million. Merus had a negative return on equity of 44.13% and a negative net margin of 390.36%. On average, sell-side analysts forecast that Merus will post -3.12 EPS for the current fiscal year.

Insider Transactions at Merus

In related news, VP Harry Shuman sold 6,000 shares of the company’s stock in a transaction on Tuesday, June 4th. The stock was sold at an average price of $52.89, for a total value of $317,340.00. Following the sale, the vice president now directly owns 7,002 shares of the company’s stock, valued at $370,335.78. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. In the last quarter, insiders sold 14,300 shares of company stock valued at $792,792. Corporate insiders own 4.57% of the company’s stock.

Institutional Investors Weigh In On Merus

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Price T Rowe Associates Inc. MD bought a new position in shares of Merus during the first quarter valued at $53,377,000. RTW Investments LP grew its position in Merus by 90.0% in the 3rd quarter. RTW Investments LP now owns 1,996,764 shares of the biotechnology company’s stock worth $47,084,000 after purchasing an additional 945,871 shares during the period. Deerfield Management Company L.P. Series C raised its stake in Merus by 27.9% during the 3rd quarter. Deerfield Management Company L.P. Series C now owns 3,876,938 shares of the biotechnology company’s stock valued at $91,418,000 after buying an additional 845,000 shares during the last quarter. Federated Hermes Inc. lifted its holdings in shares of Merus by 26.0% during the 4th quarter. Federated Hermes Inc. now owns 3,637,309 shares of the biotechnology company’s stock valued at $100,026,000 after buying an additional 751,609 shares during the period. Finally, Artal Group S.A. purchased a new position in shares of Merus in the 1st quarter worth $20,492,000. Hedge funds and other institutional investors own 96.14% of the company’s stock.

Merus Company Profile

(Get Free Report

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.

Featured Articles

Analyst Recommendations for Merus (NASDAQ:MRUS)

Receive News & Ratings for Merus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merus and related companies with MarketBeat.com's FREE daily email newsletter.